Biotech Trials, Deals, and IPOs
Kilder
- Endpoints: AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
- Eagletribune: AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - Eagle-Tribune
- Za: AbCellera stock surges 22% on positive trial results By Investing.com - Investing.com South Africa
- Ibtimes: AbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results - International Business Times Australia
- BioPharma Dive: Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
- GEN: BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development
- News-medical: Broken String Biosciences launches BaseMap ABE to enable genome-wide off-target characterization in base editing therapeutic development - News-Medical
- GEN: Spatial Transcriptomics Uncovers Heterogeneity in Heart Transplant Rejection - Genetic Engineering and Biotechnology News
- Labiotech: We asked 19 biotech leaders what breaks their deals. It wasn’t the science.
- STAT: STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
- Raps: Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes - RAPS
- STAT: FDA panel to weigh Grail’s Galleri test - STAT
- BioPharma Dive: Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
- BioSpace: Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline - BioSpace
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.